Tetraphase Pharmaceuticals, Inc. (TTPH) Expected to Announce Quarterly Sales of $2.26 Million
Wall Street brokerages expect Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) to announce $2.26 million in sales for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Tetraphase Pharmaceuticals’ earnings, with estimates ranging from $1.50 million to $3.28 million. Tetraphase Pharmaceuticals posted sales of $1.09 million during the same quarter last year, which suggests a positive year-over-year growth rate of 107.3%. The business is scheduled to report its next earnings results on Wednesday, March 14th.
On average, analysts expect that Tetraphase Pharmaceuticals will report full year sales of $2.26 million for the current fiscal year, with estimates ranging from $6.00 million to $10.41 million. For the next financial year, analysts anticipate that the company will post sales of $6.90 million per share, with estimates ranging from $5.00 million to $12.41 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.63). The business had revenue of $4.10 million for the quarter, compared to analyst estimates of $1.59 million. Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The firm’s revenue was up 355.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.58) EPS.
A number of research analysts recently weighed in on TTPH shares. Stifel Nicolaus raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the stock from $8.00 to $15.00 in a report on Wednesday, July 26th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $13.00 price objective (up from $12.00) on shares of Tetraphase Pharmaceuticals in a report on Wednesday, July 26th. Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Thursday, July 27th. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 price objective on the stock in a report on Wednesday, August 9th. Finally, BidaskClub lowered Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $15.15.
Tetraphase Pharmaceuticals (NASDAQ TTPH) traded down $0.15 during mid-day trading on Thursday, hitting $6.15. The company had a trading volume of 127,381 shares, compared to its average volume of 440,060. Tetraphase Pharmaceuticals has a 1-year low of $3.39 and a 1-year high of $9.93.
In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 7,155 shares of the stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $5.86, for a total value of $41,928.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders have sold 33,405 shares of company stock valued at $199,691. 5.50% of the stock is owned by corporate insiders.
Institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new stake in Tetraphase Pharmaceuticals in the third quarter worth $107,000. Brighton Jones LLC purchased a new position in shares of Tetraphase Pharmaceuticals in the third quarter valued at $108,000. UBS Group AG grew its position in shares of Tetraphase Pharmaceuticals by 2.3% in the first quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 387 shares in the last quarter. AXA purchased a new position in shares of Tetraphase Pharmaceuticals in the second quarter valued at $132,000. Finally, Jane Street Group LLC purchased a new position in shares of Tetraphase Pharmaceuticals in the first quarter valued at $181,000. 42.68% of the stock is owned by hedge funds and other institutional investors.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.